Stockwatch: Market Turmoil Exposes Weak Fundamentals
This article was originally published in Scrip
The one good aspect of being away on holiday during last week's stock market turmoil was that I had the perspective of an observer of the frantic selling and buying action. However, the selling action actually started the week before last and there were more warning signs from life science companies, even during the mid-week recovery, which suggested that there may be more weakness to come.
You may also be interested in...
Lexicon’s announcement of two positive cardiovascular outcome studies was tempered by the realization that its drug is not approved in the US, nor in Europe in the diabetic populations studied.
Among big pharma there is a creeping realization that the effects of the coronavirus on revenues and prescriptions may linger. At smaller biotechs, it is patently obvious.
It is one thing to aspire to build a rival to another company’s banner therapeutic franchise, but quite another to start from the ground up, especially when your form in that area is mixed.